Jimscaline
Jimscaline, also known as C-(4,5,6-trimethoxyindan-1-yl)methanamine, is a conformationally-restricted derivative of the cactus-derived psychedelic drug mescaline, which was reported in 2006 by a team at Purdue University led by David E. Nichols. It acts as a potent agonist for the serotonin 5-HT2A and 5-HT2C receptors with the more active (R)-enantiomer having an affinity (Ki) of 69 nM at the human serotonin 5-HT2A receptor, and around three times the potency of mescaline in drug discrimination tests in animals.